On July 11, 2019 Schrödinger reported receipt of a preclinical milestone payment from Sanofi in a drug discovery program advancing as part of a multi-year, multi-target collaboration between the two companies (Press release, Schrodinger, JUL 11, 2019, View Source [SID1234537484]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the collaboration, Schrödinger provides advanced molecular simulation and computational design expertise to Sanofi across multiple stages of drug discovery, from target analysis and lead optimization to identification of a development candidate. Earlier this spring, Schrödinger announced the advancement of a separate program in autoimmune disease into clinical trials.
"This is an especially exciting moment in our collaboration with Sanofi as it marks another program advanced," said Karen Akinsanya, Ph.D., Schrödinger’s chief biomedical scientist. "Achieving this milestone is a testament to the value of our ongoing collaboration with partners and our ability to efficiently identify promising therapeutic compounds."
The work with Sanofi is one of several collaborations Schrödinger has established with leading biotech and pharmaceutical companies around the world. These collaborations leverage Schrödinger’s physics-based computational platform to enable rapid iterations of design and analysis of potential therapeutic compounds. Such collaborations have already led to several clinical-stage assets and two FDA-approved oncology drugs. More than two dozen additional programs are moving through discovery and development in indications including oncology, diabetes, metabolic disorders, schizophrenia, and neurodegenerative diseases.